Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Merck
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$152.20
52 Haftanın En Yüksek Seviyesi	US$153.50
52 Haftanın En Düşük Seviyesi	US$77.58
Beta	0.21
1 Aylık Değişim	22.35%
3 Aylık Değişim	31.34%
1 Yıllık Değişim	79.78%
3 Yıllık Değişim	36.75%
5 Yıllık Değişim	97.48%
Halka arzdan bu yana değişim	13,428.89%

Son Haberler & Güncellemeler

Anlatı Güncellemesi • Aug 12

MRK: Pipeline Execution And Patent Cliff Response Will Shape Future Earnings Balance

Merck's updated analyst price target framework now points to a fair value of $136.85, up from $132.78. Analysts link this shift to a series of higher Street targets that emphasize the company's dividend profile, pipeline progress, and M&A optionality.

Recent updates

Anlatı Güncellemesi • Aug 12

MRK: Pipeline Execution And Patent Cliff Response Will Shape Future Earnings Balance

Anlatı Güncellemesi • Jul 29

MRK: Pipeline Execution And Policy Headwinds Will Restrain Multiple Expansion

Merck's updated analyst price target reflects a modest fair value move to about $108, with analysts pointing to refreshed pipeline assumptions, sector re-rating, and multiple expansion as key drivers behind the change. Analyst Commentary Recent commentary on Merck highlights a mix of optimism around the pipeline and sector setup alongside a more cautious tone on execution risks, earnings durability, and regulatory overhangs.

Seeking Alpha • Jul 17

Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions

Summary Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. The company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio. Q1 2026 revenues grew 5% to $16.3B, led by Oncology and Animal Health, but risks remain around KEYTRUDA patent loss, new product launches, and regulatory outcomes. Read the full article on Seeking Alpha

Anlatı Güncellemesi • Jul 14

MRK: Oncology Pipeline And Patent Cliff Responses Will Shape Earnings Balance

Merck's updated analyst price target moves higher by a few dollars, reflecting modestly higher fair value estimates to $132.78, alongside generally supportive analyst views around the company's Q2 setup, sector fund flows, and long term pipeline assumptions. Analyst Commentary Analysts covering Merck are broadly constructive ahead of the upcoming Q2 report, with most recent research focused on price target updates, the earnings setup, and how the pipeline and regulatory backdrop could shape the stock's risk and reward profile.

Anlatı Güncellemesi • Jun 30

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Analysts have raised the Merck fair value estimate to $155 from $150, pointing to higher long term earnings expectations and multiple expansion, as reflected in recent Street price target increases to as high as $155. Analyst Commentary Recent Street research on Merck reflects a cluster of constructive views, with several bullish analysts lifting price targets and highlighting long term earnings potential.

Anlatı Güncellemesi • Jun 15

MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside

Analysts have nudged their price targets for Merck higher by about $3 to $15 in recent research, supporting a modest increase in the fair value estimate to $101.68. This reflects updated profit margin assumptions and a slightly lower future P/E, along with adjustments to revenue growth expectations and discount rates.

Anlatı Güncellemesi • Jun 01

MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance

Analysts have nudged their average price targets on Merck higher by $3 to $15 in recent weeks, citing updated views on the company’s oncology pipeline, the Terns Pharmaceuticals deal, and specific assets like Sac TMT that some expect could materially influence Merck’s long term earnings profile. Analyst Commentary Recent Street research around Merck clusters around two main themes, the potential of key pipeline assets like Sac TMT and TERN-701, and how recent study outcomes and deal activity could affect execution risk and valuation.

Anlatı Güncellemesi • May 21

Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026

Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.

Anlatı Güncellemesi • May 19

Merck Completes Acquisition of Terns Pharmaceuticals

Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.

Anlatı Güncellemesi • May 17

MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance

Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.

Analiz Makalesi • May 11

Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...

Anlatı Güncellemesi • May 02

MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple

Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.

Anlatı Güncellemesi • Apr 19

Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)

Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.

Anlatı Güncellemesi • Apr 18

MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple

Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.

Anlatı Güncellemesi • Apr 04

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.

Anlatı Güncellemesi • Mar 21

MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple

The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.

Anlatı Güncellemesi • Mar 06

MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside

Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.

Anlatı Güncellemesi • Feb 20

MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance

Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.

Anlatı Güncellemesi • Feb 06

MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple

Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.

Anlatı Güncellemesi • Jan 23

MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance

Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.

Anlatı Güncellemesi • Jan 09

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.

Hissedar Getirileri

	MRK	US Pharmaceuticals	US Pazar
7D	14.5%	2.3%	-0.3%
1Y	79.8%	53.6%	19.9%

Getiri vs. Endüstri: MRK geçen yıl % 53.6 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: MRK geçen yıl % 19.9 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	9.0%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MRK son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MRK 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1891	74,000	Rob Davis	www.merck.com

Merck & Co., Inc. dünya çapında bir sağlık şirketi olarak faaliyet göstermektedir. Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq adı altında çeşitli alanlarda insan sağlığı ilaçları sunmaktadır, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia ve Janumet markaları. Şirket ayrıca Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine markaları altında hayvancılık ürünleri gibi veteriner ilaçları, aşılar ve sağlık yönetimi çözümleri ve hizmetleri de sunmaktadır, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox ve Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt markaları; Allflex Livestock Intelligence çözümleri; ve Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune markaları altında eşlik eden hayvan ürünleri, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare ve Home Again markaları.

Merck & Co., Inc. Temel Bilgiler Özeti

Merck'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MRK temel i̇stati̇sti̇kler
Piyasa değeri	US$333.49b
Kazançlar(TTM)	US$3.17b
Gelir(TTM)	US$66.57b

118.3x

F/K Oranı

5.6x

P/S Oranı

MRK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MRK gelir tablosu (TTM)
Gelir	US$66.57b
Gelir Maliyeti	US$16.04b
Brüt Kâr	US$50.53b
Diğer Giderler	US$47.35b
Kazançlar	US$3.17b

Son Raporlanan Kazançlar

Jun 30, 2026

Sonraki Kazanç Tarihi

Oct 29, 2026

Hisse başına kazanç (EPS)	1.29
Brüt Marj	75.90%
Net Kâr Marjı	4.77%
Borç/Özkaynak Oranı	128.4%

MRK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.2%

Mevcut Temettü Verimi

259%

Ödeme Oranı

MRK güvenilir bir temettü ödüyor mu?

MRK temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman MRK satın almanız gerekir?
Merck temettü tari̇hleri̇
Eski Temettü Tarihi	Sep 15 2026
Temettü Ödeme Tarihi	Oct 07 2026
Eski temettüye kadar geçen günler	26 days
Temettü ödeme tarihine kadar geçen günler	48 days

MRK güvenilir bir temettü ödüyor mu?

MRK temettü geçmişine ve kıyaslamalara bakın

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/19 02:52
Gün Sonu Hisse Fiyatı	2026/08/19 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Merck & Co., Inc. 49 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Charles Butler	Barclays
Emily Field	Barclays

Merck (MRK) Hisse Özeti

Ödüller

Risk Analizi

Analyst Price Targets

US Investments And New Product Launches Will Shape Future Markets

Global Pricing Pressures Will Erode Margins Amid Rising Regulatory Scrutiny

Aging Populations And Biotech Breakthroughs Will Drive Expansion

Top Community Narratives

Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges

Top Community Narratives

Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges

Top Analyst Narratives

US Investments And New Product Launches Will Shape Future Markets

Global Pricing Pressures Will Erode Margins Amid Rising Regulatory Scrutiny

Aging Populations And Biotech Breakthroughs Will Drive Expansion

Merck & Co., Inc. Rakipler

Johnson & Johnson

Pfizer

Bristol-Myers Squibb

Eli Lilly

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Merck Reports Major Phase 3 Win for Personalized mRNA Cancer Vaccine in Melanoma Trial

MRK: Pipeline Execution And Patent Cliff Response Will Shape Future Earnings Balance

Insider recently sold US$2.0m worth of stock

FDA and EMA Review Merck Application to Expand ENFLONSIA RSV Use in Young Children

Insider notifies of intention to sell stock

Merck Ends Phase III Trodelvy Keytruda Lung Cancer Trial After Unpromising Results

Recent updates

Merck Reports Major Phase 3 Win for Personalized mRNA Cancer Vaccine in Melanoma Trial

MRK: Pipeline Execution And Patent Cliff Response Will Shape Future Earnings Balance

Insider recently sold US$2.0m worth of stock

FDA and EMA Review Merck Application to Expand ENFLONSIA RSV Use in Young Children

Insider notifies of intention to sell stock

Merck Ends Phase III Trodelvy Keytruda Lung Cancer Trial After Unpromising Results

Merck Announces Health Canada Approval Of KEYTRUDA For Muscle Invasive Bladder Cancer Ineligible For Cisplatin Chemotherapy In Combination With Enfortumab Vedotin As Neoadjuvant And Adjuvant Treatment

Health Canada Approves Keytruda Combination for Muscle-Invasive Bladder Cancer in Eligible Adults

Merck & Co., Inc. Updates Earnings Guidance for 2026

Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.85 announced

Merck & Co., Inc. Announces Quarterly Dividend for the Fourth Quarter of 2026, Payable on October 7, 2026

MRK: Pipeline Execution And Policy Headwinds Will Restrain Multiple Expansion

Merck Signs Global Licensing Deals for Monthly Oral HIV PrEP Alimatravir in Phase 3

Consensus EPS estimates increase by 75%

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

Merck and Phanes Expand Trial to Test New Combo Therapy for Biliary Tract Cancer

Merck Wins FDA Approval for First Oral PCSK9 Cholesterol Drug Lipfendra

Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions

Merck & Co., Inc. Receives U.S. FDA Approval For LIPFENDRA (Enlicitide) As The First Once-Daily Oral PCSK9 Inhibitor To Reduce LDL-C In Adults With Hypercholesterolemia

MRK: Oncology Pipeline And Patent Cliff Responses Will Shape Earnings Balance

Merck Receives Fda Approval for Keytruda and Keytruda Qlex Each with Padcev as Treatment Before and After Surgery for Adults with Muscle-Invasive Bladder Cancer

Consensus EPS estimates fall by 33%

Merck Expands HIV Therapy Access With New IDVYNSO Agreement in US Program Network

Merck Reports Positive Tulisokibart Phase 3 Result and Wins New KEYTRUDA Oncology Approvals

Consensus EPS estimates increase by 21%

US Lawmakers Open National Security Probe Into Merck Clinical Trials in China

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Merck Receives European Commission Approval For KEYTRUDA Plus Padcev as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen For Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

FDA Approves KEYTRUDA WELIREG Combo for Early-Stage Renal Cell Carcinoma

Merck Reports Positive Topline Results From The Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active Ulcerative Colitis

Merck Receives U.S. FDA Approval for Expanded Indication of CAPVAXIVE Pneumococcal 21-Valent Conjugate Vaccine in Children and Adolescents Aged 2 Through 17 At Increased Risk for Pneumococcal Disease

MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside

Merck Receives Fda Approval for KEYTRUDA, KEYTRUDA QLEX, and WELIREG Combinations for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma

Merck Gains FDA Clearance for Kidney Cancer Combo and Expands Poultry Device Business

Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment

Merck Pursues Growth With Terns Deal and Expanding Pipeline as Keytruda Patent Expiry Nears

MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance

Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation

First quarter dividend of US$0.85 announced

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2026, Payable on July 8, 2026

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer

Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer

Merck Completes Acquisition of Terns Pharmaceuticals

MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026

Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture

Merck & Co., Inc. Updates Earnings Guidance for the Full Year 2026

MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple